Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Mobilization, Harvesting and Transplantation of Peripheral Blood Stem Cells in Patients with Severe Refractory Systemic Lupus Erythematosus - A Single Center Experience.

A Retrospective Study of Autologous Stem Cell Mobilization by G-CSF in Combination with Chemotherapy in Patients with Multiple Myeloma and Lymphoma.

Treatment and Follow‐up of 18 Severe Systemic Lupus Erythematosus Patients with Stem Cell Transplantation

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Autologous Peripheral Blood Stem Cell Transplantation for Systemic Lupus Erythematosus

Transplantation of purified CD34+ stem cells from autologous peripheral blood for treatment of systemic lupus erythematosus]

Nonmyeloablative Allogeneic Stem Cell Transplantation for A Case of Refractory Systemic Lupus Erythematosus

Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis

[Application of CD34+ Autologous Peripheral Progenitor Cell Transplant in the Treatment of Children with Refractory SLE].

Treatment of systemic lupus erythematosus with autologous peripheral blood stem cell transplantation

Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus

High dose of CE regimen combined with autologous hematopoietic stem cell transplantation pretreated with in vivo removal of T cells in the treatment of systemic lupus erythematosus

Allogenic Mesenchymal Stem Cells Transplantation in Refractory Systemic Lupus Erythematosus: a Pilot Clinical Study

Mesenchymal SCT Ameliorates Refractory Cytopenia in Patients with Systemic Lupus Erythematosus

Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy

Treatment of severe primary Sjgren syndrome with peripheral blood stem cell transplantation

[A Preliminary Study on the Treatment of Severe Autoimmune Disease by Autologous Peripheral CD(34)(+) Cell Transplantation].

Primary report on the application of CD34 + autologous peripheral progenitor cell transplant in the treatment of children with refractory SLE

Long-term follow-up of autologous peripheral blood hematopoietic stem cell transplantation for refractory lupus nephritis—a series study of 20 patients